Physician profile
Paul E Cundey
NPI 1063447464
$4,452.57
in general payments reported to CMS, 2019-2025
27 companies · $692 in 2025
The $692 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,486 · 2020: $161 · 2021: $144 · 2022: $138 · 2023: $1,584 · 2024: $247 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,510 · Travel and Lodging: $1,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,510.41 |
| Travel and Lodging | $1,012.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,412.73 | 2021-2025 | Rotablator Rotational Atherectomy System Console Kit, Opticross, Watchman Flx |
| Abbott Laboratories | $1,087.57 | 2019 | |
| Novartis Pharmaceuticals Corporation | $262.13 | 2022-2025 | |
| Medtronic, INC. | $182.88 | 2022-2025 | Cobalt Dr Mri Surescan, Corevalve Evolut R |
| Astrazeneca Pharmaceuticals LP | $166.38 | 2019-2023 | Farxiga |
| Cardiva Medical, INC. | $157.02 | 2023-2025 | Optowire, Cardiva Vascade 6/7f Vcs, Savvywire |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $153.13 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $111.58 | 2019-2025 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $98.90 | 2024-2025 | Opsumit, Opsynvi, Uptravi |
| Amgen INC. | $98.63 | 2019-2025 | Repatha |
| Pfizer INC. | $95.32 | 2019-2025 | |
| Ekos Corporation | $93.15 | 2019 | |
| Philips North America LLC | $85.97 | 2022-2025 | Ecc Solutions |
| Merck Sharp & Dohme LLC | $82.07 | 2023-2025 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $60.29 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $47.24 | 2025 | |
| Medtronic Vascular, INC. | $46.16 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $45.37 | 2023 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.37 | 2019 | |
| Cvrx, INC. | $20.64 | 2025 | Barostim Neo System |
| Terumo Medical Corporation | $19.55 | 2025 | Glidewire, Angio-Seal |
| Sanofi-Aventis U.S. LLC | $19.11 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.70 | 2025 | |
| Aegerion Pharmaceuticals, INC. | $17.55 | 2019 | |
| Astellas Pharma US INC | $17.54 | 2019 | |
| Amarin Pharma, INC. | $11.54 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Cundey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.